Angelini’s investments will be made through its Angelini Ventures arm. EIB and Angelini plan to support between seven and 10 ...

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...

Though artificial intelligence has long made a name for itself in imaging—with hundreds of programs able to automate separate ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement | Akebia Therapeutics has struck a deal for Q32 ...

Researchers said they have uncovered a novel sign of chronic stress and its damaging effects on the body by using an ...

Belite linked tinlarebant to a 35.7% reduction in lesion growth rate versus placebo, achieving the study’s primary endpoint.

Protego Biopharma is gearing up to bring its amyloid light-chain (AL) amyloidosis prospect into pivotal testing using its new ...

Single-use technologies (SUT) are well-suited for modular production environments and represent a valuable solution in ...

Clinical trials succeed or stall based on one factor that’s easy to overlook: how well they fit into patients’ lives. | ...

As the FDA's Commissioner's National Priority Voucher (CNPV) program has picked up steam, with 15 companies now having ...

ARPA-H is seeking proposals from experts in surgery, imaging and AI, including academic and scientific research institutions ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...